Pfizer price target lowered to $44 from $45 at Morgan Stanley

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Pfizer to $44 from $45 and keeps an Equal Weight rating on the shares after adjusting the firm’s models for recent IQVIA trends as well as intraquarter updates. Within the large cap pharma group, the firm sees a need to remain selective and believes that companies that can deliver growth in the second half of the decade are best positioned.